{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:17:03Z","timestamp":1794244623541,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Few studies analyzed the prognostic role of systemic inflammatory markers in early-stage ovarian cancer. The primary endpoint of the present study was to assess the prognostic impact of baseline inflammatory markers in early-stage ovarian cancer. The secondary endpoints were to compare the disease-free survival (DFS) of inflammatory markers with standard risk factors and to correlate these with BRCA mutational status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective, single-center, observational study. Patients with FIGO-stage I\u2013II and IIIA1 epithelial ovarian cancer undergoing primary surgery between 10\/2012 and 12\/2019 were included. Inflammatory markers were evaluated on the results of the complete blood count and coagulation tests, performed before ovarian cancer surgery. The Receiver Operating Characteristic curve was used to determine the optimal cut-off value of different baseline inflammatory biomarkers for the DFS analysis.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three hundred fifty-nine patients were included in the study period. Baseline neutrophil\u2013lymphocyte ratio (NLR)\u2009\u2265\u20093 and systemic immune inflammation index (SII, defined as platelet x neutrophil\u2013lymphocyte ratio)\u2009\u2265\u20091000 were associated with worse 3\u00a0year DFS and baseline SII\u2009\u2265\u20091000 was associated with worse 3\u00a0year OS. BRCA-mutated patients with SII\u2009\u2265\u20091000 and with NLR\u2009\u2265\u20093 had significantly worse DFS compared to SII\u2009&lt;\u20091000 and with NLR\u2009&lt;\u20093. FIGO stage\u2009&gt;\u2009I was the only independent risk factor for higher risk of recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SII\u2009\u2265\u20091000 and NLR\u2009\u2265\u20093 were associated with worse 3\u00a0year DFS and SII\u2009\u2265\u20091000 was associated with worse 3\u00a0year OS. The subgroups of BRCA-mutated patients with higher inflammation markers (SII\u2009\u2265\u20091000 and NLR\u2009\u2265\u20093) were associated with worse DFS. These findings might be helpful to design personalized treatment and more intensive surveillance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-022-02272-z","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T10:18:39Z","timestamp":1669198719000},"page":"314-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1727-904X","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Bizzarri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"D\u2019Indinosante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Tudisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Turchiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"6","key":"2272_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2272_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE et al (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4):284\u2013296","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2272_CR3","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e37","volume":"29","author":"S Hirose","year":"2018","unstructured":"Hirose S, Tanabe H, Nagayoshi Y et al (2018) Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer. J Gynecol Oncol 29(3):e37. https:\/\/doi.org\/10.3802\/jgo.2018.29.e37","journal-title":"J Gynecol Oncol"},{"issue":"4\u20135","key":"2272_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/CBM-2011-0212","volume":"8","author":"J Huang","year":"2010","unstructured":"Huang J, Hu W, Sood AK (2010) Prognostic biomarkers in ovarian cancer. Cancer Biomark 8(4\u20135):231\u2013251. https:\/\/doi.org\/10.3233\/CBM-2011-0212","journal-title":"Cancer Biomark"},{"issue":"1","key":"2272_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2017.10.018","volume":"362","author":"T Muinao","year":"2018","unstructured":"Muinao T, Deka Boruah HP, Pal M (2018) Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells\u2014an updated review. Exp Cell Res 362(1):1\u201310. https:\/\/doi.org\/10.1016\/j.yexcr.2017.10.018","journal-title":"Exp Cell Res"},{"issue":"6","key":"2272_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"issue":"3","key":"2272_CR7","doi-asserted-by":"publisher","first-page":"e0116206","DOI":"10.1371\/journal.pone.0116206","volume":"10","author":"MJ Proctor","year":"2015","unstructured":"Proctor MJ, McMillan DC, Horgan PG et al (2015) Systemic inflammation predicts all-cause mortality: a glasgow inflammation outcome study. PLoS ONE 10(3):e0116206. https:\/\/doi.org\/10.1371\/journal.pone.0116206","journal-title":"PLoS ONE"},{"issue":"6","key":"2272_CR8","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2272_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12885-018-4318-5","volume":"18","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Zhou S, Liu Y et al (2018) Prognostic value of systemic inflammatory markers in ovarian cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer 18(1):443. https:\/\/doi.org\/10.1186\/s12885-018-4318-5","journal-title":"BMC Cancer"},{"issue":"4","key":"2272_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11523-018-0574-1","volume":"13","author":"A Farolfi","year":"2018","unstructured":"Farolfi A, Petrone M, Scarpi E et al (2018) Inflammatory indexes as prognostic and predictive factors in ovarian cancer treated with chemotherapy alone or together with bevacizumab. A multicenter, retrospective analysis by the MITO Group (MITO 24). Target Oncol 13(4):469\u2013479. https:\/\/doi.org\/10.1007\/s11523-018-0574-1","journal-title":"Target Oncol"},{"issue":"2","key":"2272_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ygyno.2018.11.034","volume":"152","author":"D Nie","year":"2019","unstructured":"Nie D, Gong H, Mao X et al (2019) Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: a retrospective study. Gynecol Oncol 152(2):259\u2013264. https:\/\/doi.org\/10.1016\/j.ygyno.2018.11.034","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2272_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ygyno.2020.12.006","volume":"160","author":"Y Guo","year":"2021","unstructured":"Guo Y, Jiang T, Ouyang L et al (2021) A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses. Gynecol Oncol 160(3):704\u2013712. https:\/\/doi.org\/10.1016\/j.ygyno.2020.12.006","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2272_CR13","doi-asserted-by":"publisher","first-page":"e16429","DOI":"10.7759\/cureus.16429","volume":"13","author":"SO John-Olabode","year":"2021","unstructured":"John-Olabode SO, Okunade KS, Olorunfemi G et al (2021) Pretreatment neutrophil-to-lymphocyte ratio: a prognostic biomarker of survival in patients with epithelial ovarian cancer. Cureus. 13(7):e16429. https:\/\/doi.org\/10.7759\/cureus.16429","journal-title":"Cureus."},{"key":"2272_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"2272_CR15","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163\u2013170","journal-title":"Cancer Chem Rep"},{"issue":"10","key":"2272_CR16","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/cncr.23390","volume":"112","author":"JK Chan","year":"2008","unstructured":"Chan JK, Tian C, Monk BJ et al (2008) Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 112(10):2202\u20132210","journal-title":"Cancer"},{"issue":"1","key":"2272_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ygyno.2020.10.028","volume":"160","author":"N Bizzarri","year":"2021","unstructured":"Bizzarri N, du Bois A, Fruscio R et al (2021) Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecol Oncol 160(1):56\u201363. https:\/\/doi.org\/10.1016\/j.ygyno.2020.10.028","journal-title":"Gynecol Oncol"},{"key":"2272_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16022","author":"D Cerezo-Wallis","year":"2021","unstructured":"Cerezo-Wallis D, Ballesteros I (2021) Neutrophils in cancer, a love-hate affair. FEBS J. https:\/\/doi.org\/10.1111\/febs.16022","journal-title":"FEBS J"},{"key":"2272_CR19","doi-asserted-by":"publisher","first-page":"665534","DOI":"10.3389\/fonc.2021.665534","volume":"11","author":"A Braun","year":"2021","unstructured":"Braun A, Anders HJ, Gudermann T et al (2021) Platelet-cancer interplay: molecular mechanisms and new therapeutic avenues. Front Oncol 11:665534. https:\/\/doi.org\/10.3389\/fonc.2021.665534","journal-title":"Front Oncol"},{"issue":"12","key":"2272_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.trecan.2016.10.010","volume":"2","author":"GJ Yuen","year":"2016","unstructured":"Yuen GJ, Demissie E, Pillai S (2016) B lymphocytes and cancer: a love-hate relationship. Trends Cancer 2(12):747\u2013757. https:\/\/doi.org\/10.1016\/j.trecan.2016.10.010","journal-title":"Trends Cancer"},{"issue":"11","key":"2272_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668. https:\/\/doi.org\/10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2272_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431\u2013446. https:\/\/doi.org\/10.1038\/nrc.2016.52","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2272_CR23","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.1038\/s41598-021-90361-w","volume":"11","author":"C Marchetti","year":"2021","unstructured":"Marchetti C, D\u2019Indinosante M, Bottoni C et al (2021) NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. Sci Rep 11(1):11125. https:\/\/doi.org\/10.1038\/s41598-021-90361-w","journal-title":"Sci Rep"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02272-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T13:11:27Z","timestamp":1675170687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02272-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02272-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"26 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}